Opendata, web and dolomites

STRICT SIGNED

SN: The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STRICT project word cloud

Explore the words cloud of the STRICT project. It provides you a very rough idea of what is the project "STRICT" about.

biomarkers    correlation    shown    diagnosis    vitro    cvd    data    expertise    positioning    innovation    physical    survival    recruit    least    coming    20k    ivd    normal    echocardiogram    associate    regime    worldwide    25    saving    quality    competitive    killer    disease    ventricle    51    biomedical    skills    reducing    alone    secretoneurin    advantage    cardiac    surgery    market    sme    cardiovascular    lives    maturation    accurate    device    acquiring    ventricular    mortality    ask    overtreatment    house    boost    ejection    death    blood    unknowingly    pinpoint    implantable    globally    3b    assurance    global    company    trl8    activated    burden    scd    defibrillator    icds    health    cardioverter    linked    difficult    stratify    lvef    35    cardinor    arrythmia    sudden    arrhythmias    risk    caused    icd    sn    exams    victims    biomarker    patient    eligible    cardiologists    patients    patented    never    67    ecg    diagnostic    decision    status    levels    detect    lt    left   

Project "STRICT" data sheet

The following table provides information about the project.

Coordinator
CARDINOR AS 

Organization address
address: GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 119˙805 €
 EC max contribution 119˙805 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-2019-02
 Funding Scheme CSA
 Starting year 2019
 Duration (year-month-day) from 2019-12-15   to  2020-12-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDINOR AS NO (OSLO) coordinator 119˙805.00

Map

 Project objective

Cardiovascular disease (CVD) is the no. 1 killer worldwide. 25% of all CVD mortality is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival. To assess the patient’s status, cardiologists currently ask: physical exams, some cardiac biomarkers data, an ECG (which may detect an arrythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.3B€ overtreatment cost / year in the EU alone. CardiNor is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a globally patented biomarker and the only one shown to be specifically linked to ventricular arrhythmias. With SN data, cardiologists will be able to stratify patients according to their risk as well as to pinpoint high-risk patients not identified by the current diagnostic regime, thus reducing health burden costs and saving lives. CardiNor needs the SME Innovation Associate Programme to boost R&D activities within test maturation and effectively take it to TRL8. Currently, we do not have in-house expertise in biomedical device development or quality assurance. Therefore, we are looking to recruit an Innovation Associate. Acquiring these skills is important for CardiNor to maintain competitive advantage over coming years, positioning our company to high growth in the global CVD biomarkers market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

EEN OUEST H2020 (2020)

Entreprise Europe Ouest H2020

Read More  

INNOSUPPORT (2020)

Innovation Management Support for SMEs

Read More  

E3Canarias 2020-2021 (2020)

Enhancing the innovation management capacity of SMEs with the Enterprise Europe Network Canarias 2020-2021

Read More  
lastchecktime (2026-08-16 22:51:27) correctly updated